Single-probe FibroScan for measuring liver stiffness

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an international, prospective, multicenter interventional investigation enrolling about 309 adults at one Hong Kong site and three French sites to compare liver stiffness measurements (LSM) obtained with a new single probe versus the reference M and XL FibroScan probes. Participants with chronic liver disease will undergo FibroScan examinations using both the single probe and the reference probes to test reproducibility of LSM. Key exclusions include ascites, heart failure, acute hepatitis, biliary obstruction, and vulnerable patients. The primary objective is to quantify agreement and variability between the single-probe and reference-probe measurements across a broad clinical population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult patients (≥ 18 years of age).
* Patient followed with a chronic liver disease.
* Adult patient able to give his written consent.
* For European sites: patient affiliated to the healthcare system.

Exclusion Criteria:

* Vulnerable patients.
* Patients with ascites.
* Patients with heart failure.
* Patients with acute hepatitis.
* Patients with biliary obstruction.

Where it's running

• Prince of Wales Hospital the Chinese University of Hong Kong
  Hong Kong, Hong Kong Recruiting
• CHRU de Besançon
  Besançon, France Not yet recruiting
• Hôpital St Eloi- CHU Montpellier
  Montpellier, France Not yet recruiting
• Hôpital Paris Saclay
  Orsay, France Not yet recruiting

Study contacts

• Study coordinator: Anne Llorca
• Email: anne.llorca@echosens.com
• Phone: +33144827850

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Everolimus-based calcineurin-free immunosuppression one year after liver transplant

  This trial tests whether switching to or using everolimus with reduced calcineurin inhibitors after year one post-liver transplant can protect kidney function while maintaining graft health in adults at low rejection risk.

  Recruiting Phase 3 Hannover Medical School · Heidelberg, Baden-Wurttemberg and 15 other locations · NCT07739914

• Metastatic liver cancer patient registry from multiple Chinese centers

  This is a registry that collects real-world data on adults with liver metastases to understand patterns and prognosis and to support future research.

  Recruiting at 2 sites Anhui Provincial Hospital · Bengbu, Anhui and 2 other locations · NCT07602504

• Safety and how the drug behaves in adults with moderate to severe liver impairment

  This study tests the safety and how INCB123667 moves through the body when taken by adults with moderate to severe liver impairment.

  Recruiting at 4 sites Phase 1 Incyte Corporation · Chandler, Arizona and 3 other locations · NCT07559474

• Using polyene phosphatidylcholine to protect the liver after hepatectomy

  This test checks whether giving polyene phosphatidylcholine before surgery plus magnesium isoglycyrrhizinate after surgery better prevents liver injury in people having laparoscopic liver resection for hepatocellular carcinoma.

  Recruiting Phase 4 Anhui Provincial Hospital · Hefei, Anhui · NCT07150624

• CRISPR-edited donor liver transplant to reduce rejection

  This trial will try transplanting deceased-donor livers that have had key HLA genes removed with CRISPR to see if they cause less rejection in adults needing a liver transplant.

  Recruiting Phase 1/2 American Organ Transplant and Cancer Research Institute LLC · Beijing, Changping · NCT07053488

• High-protein, plant-dominant diet for people with liver cirrhosis

  This 6-month test compares a high-protein, mostly plant-based diet to a usual low-fat animal-protein diet in adults with decompensated cirrhosis who are awaiting kidney transplant to see which better preserves nutrition and muscle.

  Recruiting at 2 sites Agricultural University of Athens · Athens, Attica and 1 other locations · NCT07028580

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.